Early emergency department experience with 7-day extended-release injectable buprenorphine for opioid use disorder

Gail D'Onofrio, Jeanmarie Perrone, Kathryn F. Hawk, Ethan Cowan, Ryan McCormack, Edouard Coupet, Patricia H. Owens, Shara H. Martel, Kristen Huntley, Sharon L. Walsh, Michelle R. Lofwall, Andrew Herring

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


As the opioid overdose epidemic escalates, there is an urgent need for treatment innovations to address both patient and clinician barriers when initiating buprenorphine in the emergency department (ED). These include insurance status, logistical challenges such as the ability to fill a prescription and transportation, concerns regarding diversion, and availability of urgent referral sites. Extended-release buprenorphine (XR-BUP) preparations such as a new 7-day injectable could potentially solve some of these issues. We describe the pharmacokinetics of a new 7-day XR-BUP formulation and the feasibility of its use in the ED setting. We report our early experiences with this medication (investigational drug CAM2038), in the context of an ongoing clinical trial entitled Emergency Department-Initiated BUP VAlidaTION (ED INNOVATION), to inform emergency clinicians as they consider incorporating this medication into their practice. The medication was approved by the European Medicines Agency in 2018 and the U.S. Food and Drug Administration in 2023 for those 18 years or older for the treatment of moderate to severe opioid use disorder (OUD). We report our experience with approximately 800 ED patients with OUD who received the 7-day XR-BUP preparation in the ED between June 2020 and July 2023.

Original languageEnglish
JournalAcademic Emergency Medicine
StateAccepted/In press - 2023

Bibliographical note

Funding Information:
This research was supported by the National Institutes of Health through the NIH HEAL Initiative under award numbers UG1DA015831 and UG1DA013035. This research is also supported by the Department of Health and Human Services, National Institute on Drug Abuse, under contract numbers HHSN271201500065C & 75N95020D00012 (Clinical Coordinating Center, the Emmes Company) and 75N95019D00013 (Data and Statistics Center, the Emmes Company). Braeburn provided CAM2038 free of charge for use in the trial under a written agreement with NIDA. Funding information sm

Publisher Copyright:
© 2023 The Authors. Academic Emergency Medicine published by Wiley Periodicals LLC on behalf of Society for Academic Emergency Medicine.


  • injectable buprenorphine
  • medications for opioid use disorder
  • opioid use disorder treatment

ASJC Scopus subject areas

  • Emergency Medicine


Dive into the research topics of 'Early emergency department experience with 7-day extended-release injectable buprenorphine for opioid use disorder'. Together they form a unique fingerprint.

Cite this